NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab-Reference-Cited by-同舟云学术

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

Published:2019-05-28 Issue:1 Volume:5 Page:
ISSN:2057-3804
Container-title:Cardio-Oncology
language:en
Short-container-title:Cardio-Oncology

Author:

Bouwer Nathalie I.,Liesting Crista,Kofflard Marcel J. M.,Sprangers-van Campen Sylvia M.,Brugts Jasper J.,Kitzen Jos J. E. M.,Fouraux Michael A.,Levin Mark-David,Boersma Eric

Funder

Stichting Vriendenfonds, Albert Schweitzer Hospital

Publisher

Springer Science and Business Media LLC

Subject

Materials Science (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s40959-019-0039-4.pdf

Reference34 articles.

1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

4. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–6.

5. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, JM DC, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, 2014. Eur Heart J Cardiovasc Imaging. 15(10):1063–93.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology;Frontiers in Cardiovascular Medicine;2024-01-23

2. New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review;Cancers;2023-06-22

3. Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments;Current Oncology Reports;2023-05-30

4. Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity;Journal of Cardiovascular Development and Disease;2022-10-29

5. Early Predictive Value of NT-proBNP Combined With Echocardiography in Anthracyclines Induced Cardiotoxicity;Frontiers in Surgery;2022-07-01